Yonhap Infomax NewsAug 1, 2025
Chong Kun Dang Pharmaceutical saw Q2 operating profit fall 21.9% to 22.1 billion won as higher R&D costs offset revenue gains from milestone payments.
#YonhapInfomax #ChongKunDang #OperatingProfit #Q2Earnings #RDExpenses #MilestonePayments #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=75194
Chong Kun Dang Reports Q2 Operating Profit of 22.1 Billion Won, Down 21.9%—'R&D Expenses Rise'

Chong Kun Dang Pharmaceutical saw Q2 operating profit fall 21.9% to 22.1 billion won as higher R&D costs offset revenue gains from milestone payments.

Yonhap Infomax
Yonhap Infomax NewsApr 18, 2025
Daewoong Pharmaceutical seeks to raise up to 180 billion won through corporate bonds, showing confidence in performance amid facility investments and R&D expansion
#YonhapInfomax #DaewoongPharmaceutical #CorporateBonds #FacilityInvestment #RDExpenses #PerformanceOutlook #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=59313
Daewoong Pharmaceutical Seeks to Raise Up to 180 Billion Won, Confident in Performance

Daewoong Pharmaceutical seeks to raise up to 180 billion won through corporate bonds, showing confidence in performance amid facility investments and R&D expansion

Yonhap Infomax